📰 David Angulo News
Page 2 - David Angulo News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from David Angulo. Real-time updates on events, politics, business and more.
June 15, 2023
JERSEY CITY, N.J., June 15, 2023 -- SCYNEXIS, Inc. , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today... | June 16, 2023
May 11, 2023
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment
March 31, 2023
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ... | March 31, 2023
March 30, 2023
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with... | March 30, 2023
March 30, 2023
GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.
November 10, 2022
SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr.
November 7, 2022
07.11.2022 - Ibrexafungerp demonstrates activity against deadly fungal pathogens included in the World Health Organization’s (WHO) first fungal pathogens priority listJERSEY CITY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) - SCYNEXIS, Inc. (NASDAQ: SCYX), a ... Seite 1
October 24, 2022
24.10.2022 - Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with ibrexafungerp.All-cause mortality analysis shows 94.6% survival 30 days ... Seite 1
October 20, 2022
20.10.2022 - SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date ... Seite 1
April 22, 2022
22.04.2022 - Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting.Ongoing FURI and CARES studies are a key component of the SCYNEXIS ... Seite 1